UK's Oxford BioMedica 2025 revenue beats on lentiviral manufacturing growth

Oxford BioMedica

26/03/2026 07:12

Overview

UK cell and gene therapy CDMO's preliminary 2025 revenue grew 33%, beating analyst expectations

Operating EBITDA turned positive, driven by revenue growth and disciplined cost control

Company acquired FDA-approved viral vector facility in Durham, NC, expanding US manufacturing capabilities

Outlook

Oxford BioMedica expects FY 2026 revenue of £220-240 mln and operating EBITDA margin of about 10%

Company says 2026 revenues and EBITDA will be second-half weighted due to technology transfers and Durham ramp-up

Oxford BioMedica sees medium-term revenue growth of 25-30% in FY 2027-28 and EBITDA margin at least 20% in FY 2027

Result Drivers

LENTIVIRAL MANUFACTURING GROWTH - Revenue growth driven by increased lentiviral vector GMP manufacturing supporting clinical and commercial launch programmes

CLIENT PROGRAMME ADVANCEMENT - Higher development revenues from clients progressing through clinical development, including process characterisation and validation work

PROCUREMENT AND STORAGE SERVICES - Growth in procurement and storage services as clients prepared for commercialisation and ensured stability of raw material supply

Company press release: ID:nRSZ1697Ya

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Beat
GBP 168.70 mln
GBP 166.22 mln (8 Analysts)
FY Operating EBITDA
GBP 2.30 mln
FY Operating Profit
-GBP 22.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Oxford Biomedica PLC is GBp803.00, about 32.5% above its March 25 closing price of GBp606.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)